Fund moves

Ovid Therapeutics (OVID): Eventide Asset Management, LLC added to its stake +5.63M shares

Eventide Asset Management, LLC added to its stake in Ovid Therapeutics, per its Q1 2026 13F.

9.92M
Shares reported · +5.63M vs prior quarter
0.36%
Disclosed portfolio weight
$22M
Reported value
Holdings as of
Mar 31, 2026
Filed
May 15, 2026

What stands out in this filing

  • 4,285,000 shares in Q4 2025, 9,916,911 now (+131.4% in share count).
  • Reported at $22M, 0.36% of the portfolio value in this 13F filing.
  • No other tracked manager reported the same kind of change for Q1 2026.

Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Mar 17, 2026Company filing · Form 8-K · Material agreement, ResultsSigned an important agreement, and reported its results (and 1 more item)

What came next

  1. May 29, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On May 29, 2026, the Board of Directors (the “Board”) of Ovid Therapeutics Inc. (the “Company”) approved, effective as of June 15, 2026, an increase in the size of the Board and, upon recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), the appointment of Anna Greka, M.D., Ph.D., as a Class III director of the Company, with her term expiring at the Company’s…”
  2. Jul 5, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On July 5, 2026, Ovid Therapeutics Inc. (the “Company”) and Jeffrey Rona, who served as the Company’s Chief Business and Financial Officer, principal financial officer, principal accounting officer and secretary, mutually agreed to Mr. Rona’s transition from such roles with the Company, effective July 6, 2026 (the “Separation Date”).”
View the official recordSEC Form 13F-HR

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Ovid Therapeutics

For Ovid Therapeutics, OQRO holds 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its OVID page.

How this filing works

Explore the data

Common questions

What does this filing report about Ovid Therapeutics (OVID) stock?

Eventide Asset Management, LLC added to its stake in Ovid Therapeutics, per its Q1 2026 13F. Now 9.92M shares, $22M reported value, 0.36% of disclosed portfolio.

When did it happen, and when was it made public?

Holdings as of: Mar 31, 2026. Filed: May 15, 2026.

What stands out in this filing?

4,285,000 shares in Q4 2025, 9,916,911 now (+131.4% in share count). Reported at $22M, 0.36% of the portfolio value in this 13F filing. No other tracked manager reported the same kind of change for Q1 2026.

Is this a trade made on a known date?

No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.

Where does this information come from?

From the SEC Form 13F-HR, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Ovid Therapeutics recently?

For Ovid Therapeutics, OQRO holds 1 fund holdings report (13F) dated in the last 90 days. They are listed on the OVID page.

Does this mean OVID stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Ovid Therapeutics

Everything OQRO holds on this company is on its OVID page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data